Filing Analysis
LifeMD, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2026, and provided an updated investor presentation.
📋 Key Facts
- Announced financial results for the second quarter (three months) and first half (six months) of 2026.
- Furnished an investor presentation to be used in communications with investors and analysts starting August 5, 2026.
- Filed under Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure).
LifeMD, Inc. has entered into a strategic co-marketing collaboration with Antares Pharma (a subsidiary of Halozyme, Inc.) to support a direct-to-patient self-pay program for XYOSTED® testosterone injections. The program is scheduled to launch in July 2026 across 37 states.
🚩 Red Flags
- Termination clause linked to failure to meet budgeted marketing investments for two consecutive quarters could create operational pressure or partnership instability.
📋 Key Facts
- Agreement includes a Master Services Agreement, Statement of Work, and Specialty Pharmacy Services Agreements with Antares Pharma, Inc.
- LifeMD will serve as the exclusive telehealth co-marketing partner for the XYOSTED self-pay program.
- The program involves clinical evaluation via LifeMD's affiliated medical group and dispensing via LifeMD's pharmacy.
- Initial term is three years with automatic one-year renewals unless 90 days' notice is provided.
- A joint steering committee will oversee marketing investments; failure to meet budgeted investments for two consecutive quarters allows for termination.
LifeMD, Inc. announced its financial results for the first quarter ended March 31, 2026, and furnished an updated investor presentation. The filing serves as a routine disclosure of quarterly performance and marketing materials for the investment community.
📋 Key Facts
- Reported financial results for the three months ended March 31, 2026, on May 6, 2026.
- Furnished a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2).
- The investor presentation is intended for use in meetings with analysts and investors starting May 6, 2026.
- The filing was signed by Chief Financial Officer Atul Kavthekar.
LifeMD announced the resignation of CFO Marc Benathen and the immediate appointment of Atul Kavthekar as his successor. The transition includes a 6-12 month advisory agreement for the outgoing CFO and the promotion of two other executives to C-suite roles.
🚩 Red Flags
- Departure of a key financial officer (CFO).
- Significant monthly transition fee ($38,117) for the outgoing CFO, totaling up to $457,404 annually.
📋 Key Facts
- CFO Marc Benathen resigned effective March 31, 2026, to pursue a new opportunity.
- Atul Kavthekar appointed as new CFO effective March 16, 2026, with a $500,000 base salary.
- Outgoing CFO Benathen will receive $38,117 per month for transition advisory services for up to 12 months.
- New CFO Kavthekar was granted 675,000 RSUs, split equally between time-based and performance-based vesting.
- Jessica Friedeman was promoted to Chief Business Officer and Chris Pisano to Chief Marketing Officer.
LifeMD, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided earnings guidance for the fiscal year 2026. The company also furnished an updated investor presentation for use in upcoming analyst and investor meetings.
📋 Key Facts
- Reported financial results for the three months and year ended December 31, 2025, on March 9, 2026.
- Issued earnings guidance for the full year 2026.
- Furnished an investor presentation as Exhibit 99.2 to be used starting March 9, 2026.
- The filing was made under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
LifeMD, Inc. entered into a $30 million senior secured revolving credit facility with Citizens Bank, N.A. to support corporate development and shareholder value initiatives. The facility matures in January 2029 and includes an option to increase the principal by up to $20 million.
🚩 Red Flags
- The agreement imposes restrictions on the company's ability to incur additional debt, make investments, or dispose of assets.
📋 Key Facts
- Entered into a Credit Agreement with Citizens Bank, N.A. on January 2, 2026.
- The facility is a senior secured revolving credit line for an aggregate amount not exceeding $30 million.
- An option exists to increase the total principal amount by up to $20 million.
- Maturity date is set for January 2, 2029.
- Interest rates are variable based on Term SOFR or Alternate Base Rate plus a margin (1.50% to 2.25% for SOFR).
- Includes financial covenants: Consolidated Leverage Ratio ≤ 2.50:1 and Consolidated Interest Coverage Ratio ≥ 3.00:1, starting Q1 2026.
- As of the closing date (Jan 2, 2026), no funds have been drawn.
LifeMD, Inc. filed an 8-K to announce the release of its financial results for the three and nine months ended September 30, 2025.
📋 Key Facts
- Report date: November 17, 2025
- Financial period covered: Three and nine months ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
LifeMD, Inc. has announced the rescheduling of its Q3 2025 earnings release due to identified errors in revenue recognition stemming from data system migrations. The company expects a cumulative impact of approximately $4.6 million on prior period revenues.
🚩 Red Flags
- Revenue recognition errors in prior periods (2024 and H1 2025) indicate potential weaknesses in internal controls over financial reporting.
- Late filing of Form 10-Q (imminent Form 12b-25).
- Data system migration issues causing accounting discrepancies.
📋 Key Facts
- Rescheduled Q3 2025 earnings release and conference call to November 17, 2025.
- The company intends to file Form 12b-25 for late filing of its Form 10-Q for the period ended September 30, 2025.
- Errors identified in revenue recognition and offsetting balance sheet accounts for the periods ending Dec 31, 2024, and June 30, 2025.
- Cumulative impact of adjustments is approximately $4.6 million (approx. 1.4% of cumulative revenue during those periods).
- Management asserts that adjustments will not materially impact revenue guidance or cash flow/cash position.
LifeMD, Inc. has entered into a definitive agreement to sell an 80% interest in WorkSimpli Software LLC to Lion Buyer, LLC for an enterprise value of approximately $65.0 million. The transaction includes a significant portion of contingent consideration based on future performance targets.
🚩 Red Flags
- Significant portion of the deal (53.8%) is contingent upon future performance targets, creating uncertainty in total realized value.
📋 Key Facts
- LifeMD is selling its 80% stake in WorkSimpli Software LLC (the 'Company') to Lion Buyer, LLC.
- Total enterprise value for the units is approximately $65.0 million.
- Cash component at close: $24.0 million (subject to adjustments); LifeMD's pro rata share is $22.0 million.
- Performance-based consideration: Up to $26.0 million based on Adjusted EBITDA targets through 2028; LifeMD's pro rata share is up to $23.8 million.
- Activation amount: Up to $2.0 million based on subscription targets; LifeMD's pro rata share is up to $1.8 million.
- Total potential aggregate consideration for Sellers: Up to $52.0 million.
LifeMD, Inc. has dismissed CBIZ CPAs P.C. and appointed PricewaterhouseCoopers LLP (PwC) as its new independent registered public accounting firm. The dismissal follows a period of rapid auditor turnover, with Marcum LLP also being dismissed in April 2025.
🚩 Red Flags
- High auditor turnover: The company has changed auditors twice in the last four months (Marcum LLP in April, CBIZ CPAs in August).
- Reported material weaknesses in internal controls over financial reporting (ITGCs and IPE).
- Potential instability in financial oversight given the rapid succession of auditor dismissals.
📋 Key Facts
- Dismissed CBIZ CPAs P.C. on August 15, 2025.
- Appointed PricewaterhouseCoopers LLP (PwC) on August 18, 2025, for the fiscal year ending December 31, 2025.
- The company reported material weaknesses in internal control over financial reporting related to IT general controls (user access/change management) and business process controls regarding Information Produced by the Entity (IPE).
- CBIZ CPAs did not issue an audit report prior to dismissal.
- Marcum LLP was previously dismissed on April 24, 2025.
LifeMD, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2025. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Report date: August 5, 2025
- Reporting period: Three and six months ended June 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Signed by Marc Benathen, Chief Financial Officer
LifeMD, Inc. announced the appointment of Shayna Webb Dray as Chief Operating Officer (COO), effective March 27, 2025. The announcement includes details regarding her compensation package and a new Restricted Stock Unit (RSU) award agreement.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Shayna Webb Dray appointed COO effective March 27, 2025.
- Ms. Webb Dray previously served as SVP of Operations and Head of Supply Chain & Procurement at LifeMD.
- Base salary set at $400,000 per annum.
- Awarded 100,000 Restricted Stock Units (RSUs) via a new agreement dated July 27, 2025.
- RSU vesting schedule includes time-based tranches and performance-based tranches tied to annualized EBITDA targets for the healthcare business by Dec 31, 2027.
LifeMD, Inc. held its annual meeting of stockholders on June 13, 2025. Stockholders approved the election of seven directors and the ratification of CBIZ CPAs, P.C. as the independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual meeting held on June 13, 2025.
- Quorum was established by a majority in interest of all stock issued and outstanding.
- Proposal 1: Election of seven directors (Justin Schreiber, Dr. Joseph V. DiTrolio, Roberto Simon, John R. Strawn, Jr., Dr. Joan LaRovere, William Febbo, and Dr. Calum MacRae) was approved.
- Proposal 2: Ratification of CBIZ CPAs, P.C. as the independent registered public accounting firm for FY2025 was approved with 31,541,717 votes in favor.
LifeMD, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of the release of quarterly earnings via press release.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025
- Filing date: May 6, 2025
- The filing includes an announcement of financial results through Exhibit 99.1 (Press Release)
- Company is listed on the Nasdaq Global Market under ticker LFMD
LifeMD, Inc. has entered into an agreement to acquire the assets of Optimal Human Health MD, a virtual women's health provider. The transaction is structured primarily through equity issuance and performance-based earn-outs.
🚩 Red Flags
- Potential dilution for existing shareholders through multiple tranches of stock issuance (up to 300,000 total shares via acquisition and earn-outs).
- Complexity of earn-out milestones involving both patient volume and revenue targets.
📋 Key Facts
- Acquisition of assets from OHHMD, PLLC (Optimal Human Health MD) closed on April 25, 2025.
- Consideration includes 100,000 shares of LifeMD common stock: 50,000 issued at closing and 50,000 to be issued on the first anniversary.
- Earn-out provisions include up to 200,000 additional shares contingent on reaching specific patient counts (2,500 or 5,000) and revenue milestones ($2.5M or $4.5M quarterly).
- Dr. Doug Lucas will join as VP of Female Health & Clinical Operations via a three-year employment agreement.
- At least 75% of the Seller's employees and independent contractors have accepted employment offers.
LifeMD, Inc. announced the resignation of its independent auditor, Marcum LLP, effective April 24, 2025. The company has appointed CBIZ CPAs P.C. as its new independent registered public accounting firm.
🚩 Red Flags
- Auditor change: Marcum LLP resigned, which is a common red flag in micro-cap companies.
- Material weaknesses identified in internal controls over financial reporting (ITGCs and IPE processes).
- Potential risk of delayed filings if the transition to CBIZ CPAs P.C. encounters friction or requires extensive remediation of material weaknesses.
📋 Key Facts
- Marcum LLP resigned as the Company's independent auditor on April 24, 2025.
- CBIZ CPAs P.C. has been engaged as the successor auditor with Audit Committee approval.
- The company reported no disagreements with Marcum regarding accounting principles or auditing procedures.
- The company disclosed material weaknesses in internal control over financial reporting related to IT general controls (user access/change management) and business process controls (IPE review/approval).
- Marcum's reports for fiscal years 2023 and 2024 did not contain adverse opinions or disclaimers.
LifeMD, Inc. filed an 8-K to announce its financial results for the three months and fiscal year ended December 31, 2024, alongside providing earnings guidance for the full year 2025.
📋 Key Facts
- Report date: March 10, 2025
- Reporting period covered: Three months and year ended December 31, 2024
- Content includes financial results and earnings guidance for 2025
- Filed under Item 2.02 (Results of Operations and Financial Condition)
LifeMD, Inc. announced a Second Amendment to the employment agreement of Chairman and CEO Justin Schreiber, effective December 24, 2024. The amendment establishes an annual base salary of $500,000 for Mr. Schreiber starting January 1, 2025.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Effective date of agreement amendment: December 24, 2024.
- CEO Justin Schreiber will receive an annual base salary of $500,000.
- Salary increase/adjustment becomes effective January 1, 2025.
- The filing includes a Second Amendment to the existing Employment Agreement.
LifeMD, Inc. announced the voluntary resignation of Robert Jindal from its Board of Directors, effective December 31, 2024.
📋 Key Facts
- Robert Jindal resigned voluntarily from the Board of Directors.
- The resignation is effective as of December 31, 2024.
- The company explicitly stated that the resignation was not due to any disagreement regarding operations, policies, or practices.
LifeMD, Inc. announced the voluntary resignation of Naveen Bhatia from its Board of Directors, effective October 25, 2024.
📋 Key Facts
- Naveen Bhatia resigned voluntarily from the Board of Directors.
- The resignation became effective on October 25, 2024.
- The company explicitly stated the resignation was not due to any disagreement regarding operations, policies, or practices.
LifeMD, Inc. reported the results of its annual meeting of stockholders held on June 14, 2024. Stockholders approved the election of nine directors, an increase in shares available under the equity incentive plan, executive compensation, and the ratification of Marcum LLP as independent auditors.
📋 Key Facts
- Annual meeting held on June 14, 2024; a quorum was present.
- Stockholders approved Proposal 2: Increasing maximum shares available under the Third Amended and Restated 2020 Equity and Incentive Plan by 3,000,000 shares.
- All nine proposed directors were elected to serve until the next annual meeting (Proposal 1).
- Ratification of Marcum LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024 (Proposal 4).
- Non-binding advisory vote on executive compensation (Say-on-Pay) was approved (Proposal 3).
LifeMD, Inc. announced the appointment of Dr. Calum MacRae to its Board of Directors on April 26, 2024. The appointment includes a multi-year equity compensation package totaling 50,000 restricted shares.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Dr. Calum MacRae appointed to the Board of Directors effective April 26, 2024.
- Compensation includes three grants under the 2020 Equity and Incentive Plan totaling 50,000 restricted shares.
- Vesting schedule for 50,000 shares: 16,500 on April 26, 2025; 16,500 on April 26, 2026; and 17,000 on April 26, 2027.
- Dr. MacRae is the Vice Chair for Scientific Innovation at Brigham and Women’s Hospital and a faculty member at Harvard Medical School.